Growth through ADME Leverage Cyprotex US expansion in 2014 and ongoing US facility investments to position cross-sell opportunities for ADME-Tox services to existing Apredica contacts and new US clients, emphasizing scale and high-throughput capabilities.

Global Brand Unification Capitalize on the brand consolidation under Cyprotex to offer integrated service packages, reduce client confusion, and present a unified global portfolio that simplifies contracting and invoicing for multinational customers.

Recent Digital Enablement Promote Cyprotex e-store and online ordering capabilities for convenient access to ADME-Tox services, aligning with clients who prefer digital procurement and faster turnaround times.

Strategic Acquisitions Highlight Evotec acquisition momentum and Cyprotex’s positioning within a larger biosciences group to attract enterprise clients seeking a broad, integrated discovery and development partner with global reach.

Low Revenue Growth Signals Target small and mid-size pharma and biotech firms with cost-effective, high-throughput ADME-Tox offerings, while offering scalable packages that fit a <$1M revenue profile and potential for growth with expanding capabilities.